Melbourne, Mar 3, 2010 (ABN Newswire) - Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that the United States Patent and Trademark Office (USPTO) has granted a key patent that provides exclusive commercial protection for its bone tissue generating products through to at least the year 2019 in the United States, the world's largest market for regenerative medicines.
